Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Chiron Corporation |
---|---|
Information provided by: | Chiron Corporation |
ClinicalTrials.gov Identifier: | NCT00054873 |
The purpose of this study is to evaluate the efficacy and safety of tezacitabine when given alone or in combination with 5-fluorouracil (5-FU) to subjects who have advanced esophageal or gastric adenocarcinoma.
Condition | Intervention | Phase |
---|---|---|
Esophageal Neoplasms Stomach Neoplasms Adenocarcinoma |
Drug: tezacitabine Drug: 5-fluorouracil |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Uncontrolled |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | TEZ001 |
Study First Received: | February 12, 2003 |
Last Updated: | July 10, 2006 |
ClinicalTrials.gov Identifier: | NCT00054873 |
Health Authority: | United States: Food and Drug Administration |
Adenocarcinoma of the esophagus or stomach |
Digestive System Neoplasms Esophageal disorder Gastrointestinal Diseases Esophageal Neoplasms 2'-deoxy-2'-(fluoromethylene)cytidine Stomach cancer Carcinoma Digestive System Diseases Stomach Diseases |
Fluorouracil Stomach Neoplasms Head and Neck Neoplasms Gastrointestinal Neoplasms Esophageal Diseases Adenocarcinoma Esophageal neoplasm Neoplasms, Glandular and Epithelial |
Antimetabolites Neoplasms by Histologic Type Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs |
Enzyme Inhibitors Immunosuppressive Agents Pharmacologic Actions Neoplasms Neoplasms by Site Radiation-Sensitizing Agents Therapeutic Uses |